NeoGenomics (NEO) Projected to Release Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) will likely be posting its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect NeoGenomics to post earnings of $0.03 per share and revenue of $196.9250 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 4:30 PM ET.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The company had revenue of $186.67 million during the quarter, compared to analysts’ expectations of $184.54 million. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, analysts expect NeoGenomics to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Price Performance

Shares of NEO stock opened at $13.89 on Friday. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41. NeoGenomics has a twelve month low of $4.72 and a twelve month high of $15.57. The company has a market cap of $1.81 billion, a P/E ratio of -18.04 and a beta of 1.74. The business has a fifty day simple moving average of $12.19 and a 200 day simple moving average of $10.65.

Insider Buying and Selling at NeoGenomics

In related news, Director Lynn A. Tetrault sold 5,307 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the sale, the director owned 91,422 shares in the company, valued at $1,032,154.38. The trade was a 5.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is currently owned by company insiders.

Institutional Trading of NeoGenomics

A number of hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC bought a new stake in shares of NeoGenomics during the second quarter worth about $32,000. Caitong International Asset Management Co. Ltd increased its stake in shares of NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after buying an additional 1,556 shares during the period. Kestra Advisory Services LLC bought a new position in NeoGenomics in the 4th quarter valued at approximately $39,000. Smartleaf Asset Management LLC raised its holdings in NeoGenomics by 77.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock valued at $42,000 after buying an additional 1,515 shares during the last quarter. Finally, Van ECK Associates Corp boosted its position in NeoGenomics by 113.8% during the 4th quarter. Van ECK Associates Corp now owns 4,921 shares of the medical research company’s stock worth $58,000 after buying an additional 2,619 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NEO. Wall Street Zen upgraded NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Leerink Partners upgraded shares of NeoGenomics from a “market perform” rating to an “outperform” rating and raised their price target for the company from $12.00 to $25.00 in a research note on Wednesday, April 29th. Benchmark lifted their price target on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Finally, Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $14.57.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.